Drug Discovery
By
Is Karyon Bio Using AI to Decode Disease Networks as Biopharma Moves Beyond Single-Target Drug Discovery?
Strategic Overview Karyon Bio is emerging as a next-generation AI-driven biotech focused on one of the industry’s most…
Is AION Labs Redefining AI Drug Discovery by Incubating Pharma-Native Startups from the Inside Out?
Strategic Overview AION Labs represents a structurally different model in the AI–biopharma landscape: a venture studio co-created by…
Is Ignota Labs Turning Pharma’s Failed Assets into a New AI-Driven Value Class?
Strategic Overview Ignota Labs is taking a fundamentally different approach to AI in biopharma—one that focuses not on…
Is XtalPi Emerging as Pharma’s AI Engine for Molecular Property Prediction and Manufacturability at Scale?
Strategic Overview XtalPi is carving out a differentiated position in the AI-biopharma landscape by focusing on one of…
Can Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
